Clinical trials: Cognitive Risk Assessment
- Condition Cognitive Risk Assessment
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Sleep Deprivation
EEG Analysis for the Objective Assessment of Drowsiness
The objective of this clinical study is to develop solutions for the evaluation and management of drowsiness, based on 2 EEG sensors only, aiming at reducing the risk of accidents related to secondary hypersomnolence (sleepiness…
- Trial name
- MEEGASAFE (NCT05453643)
- Testing
- sleep deprivation patterns
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Physip S.A